Abstract 4912
Background
AK104 is a tetravalent bispecific human IgG1 antibody, targeting two clinically validated receptors, PD-1 and CTLA-4. This bispecific antibody is designed based on Akeso Tetrabody platform (AACR, 2018). AK104 introduces novel T cell targeting MOAs that may provide an improved therapeutic index and a favorable toxicity profile when compared to the PD-1 and CTLA-4 combinations. In addition, we have shown increased avidity of AK104 binding to PD-1 and CTLA-4 compared to the combinations. The combination therapy with anti-PD-1 and anti-CTLA-4 agents is approved by FDA for metastatic melanoma, renal cell carcinoma and MSI-H/dMMR colorectal cancer. The efficacy of these drug combinations is dose dependent, and the toxicity associated with anti-CTLA-4 agents in particular is dose limiting, thereby potentially limiting full potential for combination therapy. Despite recent advances, the prognosis of patients with advanced gastric cancer remains poor. AK104 may show improved efficacy and safety in comparison to the combination of conventional anti-PD-1/L1 and anti-CTLA-4 antibodies.
Trial design
This multicenter, open-label, phase Ib/II study will evaluate the safety and efficacy of AK104 in combination with oxaliplatin and capecitabine (mXELOX) as first-line therapy in patients with advanced gastric or GEJ adenocarcinoma. The dose-escalation phase will evaluate three dose levels (4mg/kg, 6mg/kg, and 10mg/kg Q2W) to identify a maximum tolerated dose (MTD). Selected cohorts will be expanded up to a total of 18 patients per cohort to further establish the recommended Phase 2 dose (RP2D). Dose escalation and expansion phase will be followed by dose confirmation phase (Phase II) which will further characterize the treatment of AK104 in combination at RP2D. The primary endpoints are safety and efficacy (ORR in Phase II). Secondary endpoints include additional efficacy (PFS, DoR), pharmacokinetics, PD and immunogenicity. Exploratory endpoints include efficacy according to immune-related RECIST and correlations between potential biomarkers (PD-L1 expression, TMB) and clinical activity.
Clinical trial identification
NCT03852251.
Editorial acknowledgement
Legal entity responsible for the study
Peking University Cancer Hospital & Institute, Beijing, China.
Funding
Akeso Biopharma, Inc., Zhongshan, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3034 - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL STUDY
Presenter: Maria Agnese Fabbri
Session: Poster Display session 2
Resources:
Abstract
4772 - Real world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy
Presenter: Maysa Vilbert
Session: Poster Display session 2
Resources:
Abstract
5627 - Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals
Presenter: Sabela Recalde
Session: Poster Display session 2
Resources:
Abstract
3917 - Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients
Presenter: Mariana Chavez Mac Gregor
Session: Poster Display session 2
Resources:
Abstract
2246 - Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients With Breast Cancer
Presenter: Laura Spring
Session: Poster Display session 2
Resources:
Abstract
581 - The rationale for the effectiveness of systemic treatment of breast cancer depending on the body weight index
Presenter: Mohammad Hojouj
Session: Poster Display session 2
Resources:
Abstract
5327 - Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
Presenter: Silvia Mihaela Ilie
Session: Poster Display session 2
Resources:
Abstract
3613 - Pre-specified interim analysis of the SAFE trial (NCT2236806): a 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab.
Presenter: Lorenzo Livi
Session: Poster Display session 2
Resources:
Abstract
3736 - Safety of hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-center comparative study.
Presenter: Icro Meattini
Session: Poster Display session 2
Resources:
Abstract
5085 - Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab
Presenter: Isabel Blancas López-Barajas
Session: Poster Display session 2
Resources:
Abstract